Illumina Unveils TruSeq Amplicon - Analyst Blog
March 12 2012 - 11:32AM
Zacks
Illumina (ILMN) unveiled TruSeq Amplicon last
week, which is a cancer panel to aid researchers to sequence cancer
loci. This is significant since this makes sequencing possible even
in difficult samples such as formalin-fixed, paraffin embedded
(“FFPE”) tumor samples. The San Diego-based company is taking
orders for the device, shipment of which will begin next month.
Dr. Andrew Fellowes of the Department of Pathology at the Peter
MacCallum Cancer Centre in Melbourne, Australia believes that the
TruSeq cancer panel on the MiSeq system will enable them to profile
tumor samples for a wider range of mutations. Moreover, this
technology improves upon both speed and accuracy.
The introduction of TruSeq Amplicon - Cancer Panel is in sync
with Illumina's recently created Translational and Consumer
Genomics ("TCG") business, which is focused on delivering genomic
solutions to CLIA labs. This business is already working to develop
targeted resequencing panels for both MiSeq and HiSeq systems,
building on the current TruSeq Amplicon and TruSeq Enrichment
assays.
The company has been in the news over the recent past as
Roche (RHHBY) commenced a tender offer to purchase
Illumina’s outstanding shares. Earlier, Roche had made several
unsuccessful attempts to strike a deal with Illumina, but the
latter refused to participate in any substantive discussion.
Illumina introduced HiSeq 2500, a new multi-mode next-generation
sequencer earlier this year, which is slated for launch in the
second half of 2012. The DNA sequencing market is getting more
competitive as Life Technologies’ (LIFE) Benchtop
Ion Proton Sequencer is expected to hit the market in mid-2012.
These devices can sequence a human genome in a single day rather
than weeks. In addition, Illumina is also working on developing its
MiSeq platform further.
Illumina has entered into a partnership with Siemens Healthcare
Diagnostics to use the MiSeq platform for Siemens’ molecular HIV
tests. In addition, the company expanded its Genome Network with
the inclusion of British Columbia Cancer Agency to its existing
list.
Presently, Illumina retains a short-term Zacks #2 Rank
(Buy).
ILLUMINA INC (ILMN): Free Stock Analysis Report
LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From May 2024 to Jun 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Jun 2023 to Jun 2024